Summary
PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to late-stage public and private healthcare companies. PDL provides companies, academic institutions, and inventors with an immediate financial monetization of royalty streams for acquiring new income generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.
PDL BioPharma Inc (PDLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 11
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 11
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 13
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 14
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 16
Equity Offering 17
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 17
Debt Offering 18
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 18
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 19
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 21
PDL BioPharma Completes Public Offering Of Convertible Senior Notes Due 2015 For US$155 Million 21
PDL BioPharma Inc - Key Competitors 23
Key Employees 24
Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
May 03, 2017: PDL BioPharma Announces First Quarter 2017 Financial Results 26
Mar 01, 2017: PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results 28
Nov 03, 2016: PDL BioPharma Announces Third Quarter 2016 Financial Results 30
Aug 04, 2016: PDL BioPharma Announces Second Quarter 2016 Financial Results 32
May 04, 2016: PDL BioPharma Announces First Quarter 2016 Financial Results 35
Feb 22, 2016: PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results 36
Legal and Regulatory 38
Dec 19, 2016: Lensar Strategic Restructure In Partnership With Pdl Biopharma
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PDL BioPharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8
PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 11
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 11
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 13
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 14
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 16
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 17
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 18
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 19
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 21
PDL BioPharma Completes Public Offering Of Convertible Senior Notes Due 2015 For US$155 Million 21
PDL BioPharma Inc, Key Competitors 23
PDL BioPharma Inc, Key Employees 24
PDL BioPharma Inc, Subsidiaries 25List of Figures
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
